Sponsored

Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) Gains After Positive RV01 Preclinical Findings

June 02, 2025 07:56 AM BST | By Sonal Goyal
 Radiopharm Theranostics (ASX:RAD, Nasdaq:RADX) Gains After Positive RV01 Preclinical Findings
Image source: Company update

Highlights

  • RV01, a Lu177-labelled B7-H3-targeted monoclonal antibody, showed favourable biodistribution and sustained high tumour uptake in preclinical studies.
  • RV01 incorporates Fc region modifications to shorten its half-life, potentially reducing off-target radiation exposure and associated toxicities.
  • Radiopharm plans to submit an Investigational New Drug (IND) application by mid-2025, with a first-in-human basket study expected to begin by year-end.

Radiopharm Theranostics’ (ASX:RAD, Nasdaq:RADX) share price jumped over 16% to AUD 0.028 on 2 June 2025, following the release of latest preclinical data for its B7-H3-targeted radiopharmaceutical therapy, RV01.

Preclinical studies using the Lu177-B7H3-monoclonal antibody (RV01) showed favourable biodistribution and sustained high tumour uptake. The engineered modifications to the monoclonal antibody (mAb) resulted in a shorter lifespan compared to traditional mAbs. These changes, along with other Fc modifications, helps minimise off-target exposure to the isotope and reduce toxicities commonly associated with conventional mAb therapies.

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.


AI on the Rise: A Look at Top AI Companies and Their Stocks

Send OTP Resend OTP in 30s

Sponsored Articles


Investing Ideas

Previous Next